196 related articles for article (PubMed ID: 3293840)
1. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
2. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
4. Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.
Steerenberg PA; Storm G; de Groot G; Claessen A; Bergers JJ; Franken MA; van Hoesel QG; Wubs KL; de Jong WH
Cancer Chemother Pharmacol; 1988; 21(4):299-307. PubMed ID: 3370737
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
6. The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small-cell lung cancer and neuroblastoma grown as multicellular spheroids.
Russell J; Adam J; Wheldon TE; Kaye SB
Cancer Chemother Pharmacol; 1989; 23(2):111-4. PubMed ID: 2535968
[TBL] [Abstract][Full Text] [Related]
7. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
Harstrick A; Casper J; Schmoll HJ
Int J Androl; 1987 Feb; 10(1):139-45. PubMed ID: 3034790
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.
Cantwell BM; Franks CR; Harris AL
Cancer Chemother Pharmacol; 1986; 18(3):286-8. PubMed ID: 3542271
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin.
Kobayashi H; Takemura Y; Miyachi H; Ogawa T
Invest New Drugs; 1991 Nov; 9(4):313-9. PubMed ID: 1804804
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
Dedon PC; Borch RF
Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
[TBL] [Abstract][Full Text] [Related]
11. Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.
Müller LJ; Moorer-van Delft CM; Roubos EW; Vermorken JB; Boer HH
Cancer Res; 1992 Feb; 52(4):963-73. PubMed ID: 1737358
[TBL] [Abstract][Full Text] [Related]
12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
13. Interaction of two second generation platinum antitumor drugs with mouse thymocytes.
Simpkins H; Pearlman LF
Cancer Res; 1986 Mar; 46(3):1433-9. PubMed ID: 3510724
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
15. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).
Skillen AW; Buamah PK; Cantwell BM; Cornell C; Hodson AW; Harris AL
Cancer Chemother Pharmacol; 1988; 22(3):228-34. PubMed ID: 3044631
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.
Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L
Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743
[TBL] [Abstract][Full Text] [Related]
17. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro effectivity of some platinum complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1984; 31(6):641-7. PubMed ID: 6395026
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance induction and cross-resistance studies with Pt-complexes.
Hrubisko M; Balázová E; Ujházy V
Neoplasma; 1984; 31(6):649-53. PubMed ID: 6542968
[TBL] [Abstract][Full Text] [Related]
20. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
Presnov MA; Konovalova AL
Arch Geschwulstforsch; 1988; 58(1):43-9. PubMed ID: 3285804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]